drugset / Trial / NCT04930783
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Phase 1
Active not recruiting
10 enrolled
Dana-Farber Cancer Institute
Celldex Therapeutics · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma. The names of the study drugs involved in this study are: * Personalized Neoantigen peptides (which combined with poly-ICLC make the vaccine NeoVax) * Poly-ICLC (Hiltonol) * CDX-301 * Nivolumab (Opdivo) * Pembrolizumab (Keytruda)
Timeline
- Start
- 2022-01-03
- Primary completion
- 2027-12-31
- Completion
- 2030-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-301 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | NeoVax | Vaccine | — | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |